“A once-weekly option represents a meaningful advancement in how we support growth in children with Turner Syndrome, reducing the number of injections throughout that journey,” said Colleen Silk, group vice president of rare disease at Novo Nordisk.
The U.S. Food and Drug Administration approved somapacitan-beco (Sogroya) on Friday for children aged 2.5 years and older with growth failure associated with Turner syndrome.
The decision makes Sogroya the first and only once-weekly, long-acting growth hormone approved for this population, according to Novo Nordisk. The drug was previously authorized for pediatric growth hormone deficiency, idiopathic short stature, Noonan syndrome, and short stature in children born small for gestational age without catch-up growth by age two, as well as for adults with growth hormone deficiency.
REAL8 study design and primary results detailed
The approval rests on the Turner syndrome cohort of the phase 3 REAL8 study, a multicenter, randomized, open-label, active-comparator basket trial. The cohort enrolled 105 prepubertal children aged 2.5 to 10 years who had not previously received growth hormone treatment and were born small for gestational age with no catch-up growth by age two.
In a 2:1 randomization, 68 children were assigned to Sogroya at 0.24 mg/kg once weekly and 37 to daily somatropin at 0.05 mg/kg per day. That daily dose is below the maximum approved dose of 0.067 mg/kg per day for pediatric Turner syndrome patients in the United States, an important qualification on the comparison.
At week 52, the primary endpoint of mean annualized height velocity was 8.9 cm per year with Sogroya and 9.7 cm per year with daily somatropin. The estimated treatment difference was -0.8 cm per year, which Novo Nordisk characterized as nonsignificant and the growth rates as comparable. The mean change from baseline in annualized height standard deviation score, a supportive secondary endpoint, was 0.77 with Sogroya and 0.86 with somatropin.
Weekly dosing offers 313 injection-free days annually
The weekly schedule provides 313 injection-free days annually compared with daily therapy, according to trial investigator Aristides Maniatis. Prescribing information allows a missed dose to be taken within 72 hours of the scheduled day; if more than 72 hours have passed, the missed dose should be skipped and the next dose taken on the regularly scheduled day.
Sogroya is supplied in prefilled pens delivering doses of 5 mg, 10 mg, or 15 mg.
Safety Profile
Adverse reactions occurring in at least 10% of Turner syndrome patients treated with Sogroya at week 52 included respiratory tract infection, nasopharyngitis, ear infection, pyrexia, diarrhea, vomiting, and injection-site reaction. Overall, the most common side effects in children across indications include cough, common cold, diarrhea, ear infection, headache, fever, pain in extremity, injection-site reaction, respiratory tract infection, and vomiting.
In adults, common side effects include back pain, joint pain, indigestion, sleep problems, dizziness, tonsillitis, peripheral edema, vomiting, adrenal insufficiency, high blood pressure, increased creatine phosphokinase, weight gain, and anemia.
Participants are continuing in a two-year safety extension phase following the 52-week primary treatment period.
Condition Background
Turner syndrome occurs when one of the two X chromosomes is missing or partially altered. Short stature is the most common feature, generally evident by about age five. The condition occurs in about 1 in 2,000 female newborns worldwide.
Label effective immediately; long-term safety data pending
Sogroya’s expanded label is effective immediately. The ongoing two-year safety extension will provide longer-term data on growth outcomes and adverse events in this population. Novo Nordisk has not disclosed pricing changes tied to the new indication.
Sogroya for Turner Syndrome: Quick Answers
What age group is now eligible for Sogroya in Turner syndrome?
Children aged 2.5 years and older with growth failure associated with Turner syndrome.

How does the weekly injection compare to daily growth hormone in the trial?
Over 52 weeks, mean annualized height velocity was 8.9 cm/year with weekly Sogroya versus 9.7 cm/year with daily somatropin, a nonsignificant difference of -0.8 cm/year.
How many fewer injections does the weekly regimen require?
313 injection-free days per year compared with daily therapy.
What are the most common side effects in children?
Respiratory tract infection, nasopharyngitis, ear infection, pyrexia, diarrhea, vomiting, and injection-site reaction occurred in at least 10% of trial participants.
Novo Nordisk traces its origins to the 1920s with the founding of two Danish insulin laboratories, Nordisk Insulin Laboratorium and Novo Terapeutisk Laboratorium, which competed for decades before merging in 1989. The company introduced the first insulin pen device, Novopen, in 1985. Today it employs approximately 69,500 people in 80 countries and markets its products in about 170 countries.
Is long-term safety data available?
Trial participants are continuing in a two-year safety extension phase; final results are not yet published.